The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

Background Oncology guidelines suggest using the Khorana score to select ambulatory
cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) …

Venous thromboembolism (VTE) is a commonly encountered problem in patients with
cancer. In recent years, cancer treatment paradigm has shifted with most therapy offered in …

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer …

Cancer patients with venous thromboembolism (VTE) are prone to poor prognoses. Thus,
we aimed to develop a nomogram to predict the risk of VTE in these patients. We …

Patients with cancer are heterogeneous concerning the risk for VTE. Some solid
malignancies including pancreatic, lung, colon-rectum, ovarian, and brain cancer are …

Abstract Background The Khorana Score is a validated risk score for predicting 6‐month
incidence of cancer‐associated venous thromboembolism (CAT) among patients starting …

Guidelines suggest thromboprophylaxis for ambulatory cancer patients starting
chemotherapy with an intermediate to high risk of venous thromboembolism (VTE) …

Importance The assessment of the risk of venous thromboembolism (VTE) among
outpatients with cancer represents an unsolved topic. Current international guidelines …